CYP3A5 and breast cancer: The CYP3A5 non-expressing variant has been associated with reduced risk of neurotoxicity during treatment in 118 Spanish cancer patients (1/3 breast cancer) treated with paclitaxel [42], corresponding to an increased risk in expressors.